IL2 and neoplasm: The enrichment of IL-6/JAK-STAT3 and IL-2/STAT5 signaling pathways in low SIGLEC9 expression suggests that lower SIGLEC9 levels may activate pro-inflammatory pathways that support an anti-tumor immune response by enhancing cytotoxic T cell activity.